Mayo Collaborative Services v. Prometheus Laboratories
GPTKB entity
Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:argued_on |
December 7, 2011
|
| gptkbp:case_number |
10-1150
|
| gptkbp:case_outcome |
influenced legal standards
impact on innovation influenced academic research informed legal practices shaped public policy debates informed judicial reasoning affected patent law education affected patent law reform efforts affected patent litigation changed patent enforcement strategies encouraged research and development increased scrutiny on diagnostic patents influenced patent applications influenced patent office decisions influenced patent policy discussions invalidated patents limited patent scope reaffirmed natural law doctrine redefined patentable subject matter reshaped patent litigation landscape revised patent guidelines shaped future patent cases shift in patent strategy |
| gptkbp:case_types |
patent law case
|
| gptkbp:court |
gptkb:United_States_Supreme_Court
|
| gptkbp:decided_by |
gptkb:Supreme_Court_of_the_United_States
March 20, 2012 |
| gptkbp:dissenting_opinion |
gptkb:none
|
| gptkbp:has_implications_for |
future of personalized medicine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mayo Collaborative Services v. Prometheus Laboratories
|
| gptkbp:impact |
biomedical patent law
|
| gptkbp:involved_technology |
therapeutic drug monitoring
biomarkers medical tests |
| gptkbp:is_cited_in |
566 U. S. 66
|
| gptkbp:judged_by |
unanimous decision
|
| gptkbp:judicial_review |
gptkb:Supreme_Court_of_the_United_States
|
| gptkbp:legal_context |
U. S. patent law
|
| gptkbp:legal_framework |
gptkb:intellectual_property
|
| gptkbp:legal_issue |
patent eligibility
|
| gptkbp:legal_representation |
gptkb:Prometheus_Laboratories
gptkb:Mayo_Collaborative_Services |
| gptkbp:modern_relevance |
medical diagnostics
|
| gptkbp:outcome |
patent claims invalidated
|
| gptkbp:party |
gptkb:Prometheus_Laboratories
gptkb:Mayo_Collaborative_Services |
| gptkbp:precedent |
Myriad Genetics, Inc. v. Association for Molecular Pathology
limits on patenting natural correlations |
| gptkbp:public_perception |
gptkb:Justice_Stephen_Breyer
|
| gptkbp:related_cases |
gptkb:Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc.
gptkb:Bilski_v._Kappos |
| gptkbp:significance |
natural laws and phenomena
|
| gptkbp:bfsParent |
gptkb:Association_for_Molecular_Pathology_v._Myriad_Genetics
gptkb:Bilski_v._Kappos gptkb:Alice_Corp._v._CLS_Bank_International |
| gptkbp:bfsLayer |
6
|